Combination of nuchal translucency, gestational age and maternal age for the assessment of risk of trisomy 21;Utilisation conjointe de la clarte nucale, de l'age gestationnel et de l'age maternel pour l'estimation du risque de trisomie 21

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 28, Issue 5, 1999, Pages 439-445

  Faraut, T ^a   Cans, C ^b   Althuser, M ^c   Jouk, P S ^c  

^a UNIV GRENOBLE ALPES   (France)

^b Registre Handicaps Enfant Observ P   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Maternal age; Nuchal translucency thickness; Prenatal diagnosis; Trisomy 21; Ultrasound

Indexed keywords

ARTICLE; CALCULATION; FETUS; FETUS ECHOGRAPHY; GESTATIONAL AGE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; PRENATAL DIAGNOSIS; PRENATAL SCREENING; RISK ASSESSMENT; TRISOMY 21;

ADULT; DOWN SYNDROME; EVALUATION STUDIES; FEMALE; FRANCE; GESTATIONAL AGE; HUMANS; MASS SCREENING; MATERNAL AGE; MIDDLE AGED; NECK; PREGNANCY; PREGNANCY, HIGH-RISK; PREVALENCE; RISK FACTORS; ULTRASONOGRAPHY, PRENATAL;

EID: 0032694188     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. European Registration of Gongenital Anomalies (EUROCAT, 1997). 15 years of Surveillance of Congenital Anomalies in Europe 1980-1994, Report 7. Scientific Institute of Public Health-Louis Pasteur, Bruxelles.
2. Cans C, Amblard F, Devillard F, Pison H, Jalbert P, Jouk PS. Population screening for aneuploidy using maternal age and ultrasound. Prenat Diagn 1998; 18: 683-92.
3. Crandall BF, Kulch P, Tabshet K. Risk assessment of amniocentesis between 11 and 15 weeks: comparison to later amniocentesis controls. Prenat Diagn 1994; 14: 913-9.
4. Eiben SB, Hammans W, Hansen S, Trawicki W, Osthelder B, Stelzer A et al. On the complication risk of early amniocentesis versus standard amniocentesis. Fetal Diagn Ther 1997; 12: 140-4.
5. Snijders RJ, Holzgreve W, Cuckle H, Nicolaides KH. Maternal age-specific risks for trisomies at 9-14 weeks'gestation. Prenat Diagn 1994; 14: 543-52.
6. Aymé S. Apport des registres à la décision en Santé Publique : l'exemple de la trisomie 21. Rev Epidémiol Santé Publ 1996 ; 44 : S82-9.
7. Nicolaides KH, De Lourdes Brizot M, Snijders R. Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancy. Br J Obstet Gynaecol 1994; 101: 782-6.
8. Charrasson T, Ko-Kivok-Yun P, Martin F, Sarramon MF. Dépistage de la trisomie 21 par mesure de la clarté nucale au premier trimestre de la grossesse. J Gynecol Obstet Biol Reprod 1997 ; 26 : 671-8.
9. Pandya P, Snijders R, Johnson S, De Lourdes Brizot M, Nicolaides KH. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. Br J Obstet Gynaecol 1995; 102: 957-62.
10. Taipale P, Hiilesmaa V, Salonen R, Ylöstalo P. Increased nuchal translucency as a marker for fetal chromosomal defects. N Engl J Med 1997; 337: 1654-8.
11. Muller F, Bussières L. Maternal serum markers for fetal trisomy 21. Eur J Obstet Gynecol Reprod Biol 1996; 65: 3-6.
12. Haddow JE, Palomaki GE, Knight GJ, Williams J, Miller WA, Johnson A. Screening of maternal serum for fetal Down's syndrome in the first trimester. N Engl J Med 1998; 38: 955-61.
13. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet 1998; 352: 343-6.
14. Bewley S, Roberts LJ, Mackinson AM, Rodeck CH. First trimester nuchal translucency: problems with screening the general population. 1. Br J Obstet Gynaecol 1995; 102: 381-5.